Navigation Links
Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
Date:10/6/2010

NEW YORK, Oct. 6 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) (the "Company"), today announced that it intends, subject to market conditions, to offer 4,500,000 shares of its common stock pursuant to an underwriting agreement with Citi acting as the sole bookrunner.  

The Company expects to use the net proceeds from the sale of the shares for general corporate purposes.  Closing of the offering is expected to occur on or about October 11, 2010, subject to customary closing conditions.  In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 675,000 shares of common stock to cover over-allotments, if any.

The offering is being made pursuant to an effective shelf registration statement.  Before you invest, you should read the base prospectus in such shelf registration statement, the prospectus supplement, when available, and other documents the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering.  The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to the offices of Citi at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, telephone number (800) 831-9146.  Alternatively, you may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.  

About Regeneron
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
2. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
3. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
4. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
5. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
9. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
10. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
11. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... ANGELES , Sept. 19, 2014  CytRx Corporation ... development company specializing in oncology, today announced that ... present at BioCentury,s 2014 NewsMakers in the Biotech Industry ... Eastern Time. The conference will take place at the ... . A live and archived webcast ...
(Date:9/19/2014)... , Sept. 19, 2014  PCI is pleased ... (Biotec).  Biotec is a leading provider of Clinical ... in Bridgend, Wales in ... addition significantly expands PCI,s presence in the UK/EU ... by adding packaging, storage and distribution capacity, as ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... Dec. 29, 2010 Reportlinker.com announces that a ... catalogue: Women,s Health Diagnostic Testing ... The purpose of this TriMark Publications report is ... vitro diagnostics (IVDs) market called women,s health testing. ...
... Reportlinker.com announces that a new market research report ... The Outlook for Pharmaceuticals in Central Asia ... Outlook for Pharmaceutical Markets in Asia is a ... Intelligence. Each report provides individual and highly-detailed analysis ...
Cached Medicine Technology:Reportlinker Adds Women's Health Diagnostic Testing 2Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 2Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 3
(Date:9/19/2014)... According to a report from HarrisMartin ... Xarelto, named as defendants in several lawsuits filed in ... the court to dismiss those suits because the alleged ... with Philadelphia.* The cases include, for instance, Fontan v. ... Comm. Pls., Philadelphia Cty.), which was brought by a ...
(Date:9/19/2014)... -- Your brain structure could help predict how willing you ... Researchers at Yale University found those with greater volume in ... may be more likely to engage in risky behavior than ... study, funded by the U.S. National Institute on Aging, involved ... the Northeast. The researchers sought to determine how brain structure ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
(Date:9/19/2014)... Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ) ... develop Type 2 diabetes continue to move forward in ... Court, District of South Carolina, Bernstein Liebhard LLP reports. ... 2014, discovery is underway and moving forward in the ... Inc., the manufacturer of Lipitor, has produced millions of ...
(Date:9/19/2014)... 2014 "I have difficulty putting in ... to stretching the skin around my eyes during the ... me to design a more convenient method of performing ... provides a quicker, easier, more sanitary method of putting ... this task manually, saves time and effort, and helps ...
Breaking Medicine News(10 mins):Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
... trees, a polluted river and a handful of concerned citizens. ... Day Sunday, //by raising its voice on various issues that ... the brink of a challenge,' said Ravi Aggarwal of Toxics ... felling of trees in the name of development needs to ...
... nine-week programme to get children especially the eight to 12-year-olds ... success. The MEND programme, as it is called, got// underway ... is opportune, considering that 30% of children in UK are ... Nutrition, and Do-it took charge of more than 1000 children. ...
... The waiting times for patients in Canada’s hospitals has ... improvement, according to the report// released by Wait Time ... stresses the importance of timely information to patients about ... ,Most hospitals have managed to keep up the target, ...
... provides permanent protection from obesity and diabetes into adulthood could ... & Industry. ,The foods, under development at ... supplemented with leptin, the hunger hormone. Those who take the ... people who are lean by nature even though they overeat? ...
... doctors and other dignitaries pledged their organs for donation at ... and Ms Gul Panag, both former Miss India, Mrs Shyama ... the first Indian to conquer North & South poles and ... ,Another unique initiative was also taken by ...
... about building casinos in the UK have not given enough ... this week’s BMJ//. ,In March the House of Lords ... Vegas-style super casino in Manchester and build 16 other casinos ... costs and benefits of liberalised gambling in the UK, but ...
Cached Medicine News:Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2Health News:MEND - Child Obesity Programme Records Success 2Health News:Baby Foods That Prevent Obesity and Diabetes in Adulthood to Hit the Market Soon 2Health News:Health Effects of Casinos Have Been Ignored: Experts 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: